The Conversation (0)
CURE Pharmaceutical announced it received its first purchase order from Meroven for the development of oral thin film delivery for several molecules.
CURE Pharmaceutical (OTCQB:CURR) announced it received its first purchase order from Meroven for the development of oral thin film delivery for several molecules.
As quoted in the press release:
Meroven has placed their first order of 150,000 units of the Vitamin D3 OTF to be distributed to the Middle East. Vitamin D is a fat-soluble vitamin that is naturally present in very few foods, added to others, and available as a dietary supplement. It is also produced endogenously when ultraviolet rays from sunlight strike the skin and trigger Vitamin D synthesis. Vitamin D promotes calcium absorption and is needed for bone growth. Vitamin D also prevents rickets in children and osteomalacia in adults. Together with calcium, Vitamin D also helps protect older adults from osteoporosis.
Additionally, a leading direct to consumer distribution company has placed an order for 867,000 melatonin blend sleep drug OTFs, to sell to distributors.
“We are thrilled that two of our development and licensing agreements are now at the stage where they will be distributing the product to people all over the world and we look forward to working with these institutions and many others on future drug developments,” said Rob Davidson, CEO of CURE. “CURE’s mission is to develop relationships with other companies to develop and commercialize new applications of proven therapeutics, all with the goal to provide greater benefit to the end user and the provider and all through our proprietary drug delivery technologies.”
Click here to read the full press release.
Source: globenewswire.com
